Pharmacokinetic equivalence study of USL255 (extended-release toipramate) when swallowed intact or when sprinkled on food.

Trial Profile

Pharmacokinetic equivalence study of USL255 (extended-release toipramate) when swallowed intact or when sprinkled on food.

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Apr 2016

At a glance

  • Drugs Topiramate (Primary)
  • Indications Epilepsy; Seizures
  • Focus Pharmacokinetics
  • Sponsors Upsher-Smith
  • Most Recent Events

    • 21 Apr 2016 Results of pooled analysis from three phase I and two phase III studies assessing the differentiating features of Topiramate (extented release capsules and immediate release) presented at the 68th Annual Meeting of the American Academy of Neurology
    • 21 Apr 2015 Results published in the media release.
    • 21 Apr 2015 According to a Upsher-Smith media release, data from this trial was presented at the 67th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top